Molecular Aspects of Cardiovascular Risk Factors

Shang-Zhong Xu,Thozhukat Sathyapalan

DOI: https://doi.org/10.3390/biom14081032

IF: 6.064

2024-08-21

Biomolecules

Abstract:Biomolecules, Vol. 14, Pages 1032: Molecular Aspects of Cardiovascular Risk Factors Biomolecules doi: 10.3390/biom14081032 Authors: Shang-Zhong Xu Thozhukat Sathyapalan Cardiovascular diseases (CVDs) are the leading cause of death [...]

biochemistry & molecular biology

What problem does this paper attempt to address?

Cellular and molecular biology of posttranslational modifications in cardiovascular disease

Li Zhu,Yong-Ping Liu,Yu-Ting Huang,Zi-Jun Zhou,Jian-Feng Liu,Li-Ming Yu,Hui-Shan Wang

DOI: https://doi.org/10.1016/j.biopha.2024.117374

Abstract:Cardiovascular disease (CVD) has now become the leading cause of death worldwide, and its high morbidity and mortality rates pose a great threat to society. Although numerous studies have reported the pathophysiology of CVD, the exact pathogenesis of all types of CVD is not fully understood. Therefore, much more research is still needed to explore the pathogenesis of CVD. With the development of proteomics, many studies have successfully identified the role of posttranslational modifications in the pathogenesis of CVD, including key processes such as apoptosis, cell metabolism, and oxidative stress. In this review, we summarize the progress in the understanding of posttranslational modifications in cardiovascular diseases, including novel protein posttranslational modifications such as succinylation and nitrosylation. Furthermore, we summarize the currently identified histone deacetylase (HDAC) inhibitors used to treat CVD, providing new perspectives on CVD treatment modalities. We critically analyze the roles of posttranslational modifications in the pathogenesis of CVD-related diseases and explore future research directions related to posttranslational modifications in cardiovascular diseases.
Exosomes and Their Derivatives As Biomarkers and Therapeutic Delivery Agents for Cardiovascular Diseases: Situations and Challenges.

Yunyang Xu,Weimin Wan,Huixuan Zeng,Ze Xiang,Mo Li,Yiwen Yao,Yuan Li,Mariza Bortolanza,Jian Wu

DOI: https://doi.org/10.2478/jtim-2023-0124

2023-01-01

Journal of Translational Internal Medicine

Abstract:Microvesicles known as exosomes have a diameter of 40 to 160 nm and are derived from small endosomal membranes. Exosomes have attracted increasing attention over the past ten years in part because they are functional vehicles that can deliver a variety of lipids, proteins, and nucleic acids to the target cells they encounter. Because of this function, exosomes may be used for the diagnosis, prognosis and treatment of many diseases. All throughout the world, cardiovascular diseases (CVDs) continue to be a significant cause of death. Because exosomes are mediators of communication between cells, which contribute to many physiological and pathological aspects, they may aid in improving CVD therapies as biomarkers for diagnosing and predicting CVDs. Many studies demonstrated that exosomes are associated with CVDs, such as coronary artery disease, heart failure, cardiomyopathy and atrial fibrillation. Exosomes participate in the progression or inhibition of these diseases mainly through the contents they deliver. However, the application of exosomes in diferent CVDs is not very mature. So further research is needed in this field.
Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Xianglai Xu,Brian Wang,Chang hong Ren,Jiangnan Hu,David A. Greenberg,Tianxiang Chen,Liping Xie,Kunlin Jin

DOI: https://doi.org/10.14336/ad.2017.0507

2017-01-01

Aging and Disease

Abstract:As with many age-related diseases including vascular dysfunction, age is considered an independent and crucial risk factor. Complicated alterations of structure and function in the vasculature are linked with aging hence, understanding the underlying mechanisms of age-induced vascular pathophysiological changes holds possibilities for developing clinical diagnostic methods and new therapeutic strategies. Here, we discuss the underlying molecular mediators that could be involved in vascular aging, e.g., the renin-angiotensin system and pro-inflammatory factors, metalloproteinases, calpain-1, monocyte chemoattractant protein-1 (MCP-1) and TGFβ-1 as well as the potential roles of testosterone and estrogen. We then relate all of these to clinical manifestations such as vascular dementia and stroke in addition to reviewing the existing clinical measurements and potential interventions for age-related vascular dysfunction.
Research progress on post-translational modification of proteins and cardiovascular diseases

XueLi Cheng,Kai Wang,Yan Zhao,Kun Wang

DOI: https://doi.org/10.1038/s41420-023-01560-5

2023-07-28

Abstract:Cardiovascular diseases (CVDs) such as atherosclerosis, myocardial remodeling, myocardial ischemia-reperfusion (I/R) injury, heart failure, and oxidative stress are among the greatest threats to human health worldwide. Cardiovascular pathogenesis has been studied for decades, and the influence of epigenetic changes on CVDs has been extensively studied. Post-translational modifications (PTMs), including phosphorylation, glycosylation, methylation, acetylation, ubiquitination, ubiquitin-like and nitrification, play important roles in the normal functioning of the cardiovascular system. Over the past decade, with the application of high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS), an increasing number novel acylation modifications have been discovered, including propionylation, crotonylation, butyrylation, succinylation, lactylation, and isonicotinylation. Each change in protein conformation has the potential to alter protein function and lead to CVDs, and this process is usually reversible. This article summarizes the mechanisms underlying several common PTMs involved in the occurrence and development of CVDs.
Cellular Senescence, Mitochondrial Dysfunction, and Their Link to Cardiovascular Disease

Maria Camacho-Encina,Laura K. Booth,Rachael E. Redgrave,Omowumi Folaranmi,Ioakim Spyridopoulos,Gavin D. Richardson

DOI: https://doi.org/10.3390/cells13040353

IF: 6

2024-02-18

Cells

Abstract:Cardiovascular diseases (CVDs), a group of disorders affecting the heart or blood vessels, are the primary cause of death worldwide, with an immense impact on patient quality of life and disability. According to the World Health Organization, CVD takes an estimated 17.9 million lives each year, where more than four out of five CVD deaths are due to heart attacks and strokes. In the decades to come, an increased prevalence of age-related CVD, such as atherosclerosis, coronary artery stenosis, myocardial infarction (MI), valvular heart disease, and heart failure (HF) will contribute to an even greater health and economic burden as the global average life expectancy increases and consequently the world's population continues to age. Considering this, it is important to focus our research efforts on understanding the fundamental mechanisms underlying CVD. In this review, we focus on cellular senescence and mitochondrial dysfunction, which have long been established to contribute to CVD. We also assess the recent advances in targeting mitochondrial dysfunction including energy starvation and oxidative stress, mitochondria dynamics imbalance, cell apoptosis, mitophagy, and senescence with a focus on therapies that influence both and therefore perhaps represent strategies with the most clinical potential, range, and utility.

cell biology
The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health

Thi Van Anh Bui,Hyesoo Hwangbo,Yimin Lai,Seok Beom Hong,Yeon-Jik Choi,Hun-Jun Park,Kiwon Ban

DOI: https://doi.org/10.4070/kcj.2023.0048

Abstract:Cardiovascular diseases (CVDs), including coronary artery disease, stroke, heart failure, and hypertension, are the global leading causes of death, accounting for more than 30% of deaths worldwide. Although the risk factors of CVDs have been well understood and various treatment and preventive measures have been established, the mortality rate and the financial burden of CVDs are expected to grow exponentially over time due to the changes in lifestyles and increasing life expectancies of the present generation. Recent advancements in metagenomics and metabolomics analysis have identified gut microbiome and its associated metabolites as potential risk factors for CVDs, suggesting the possibility of developing more effective novel therapeutic strategies against CVD. In addition, increasing evidence has demonstrated the alterations in the ratio of Firmicutes to Bacteroidetes and the imbalance of microbial-dependent metabolites, including short-chain fatty acids and trimethylamine N-oxide, play a crucial role in the pathogenesis of CVD. However, the exact mechanism of action remains undefined to this day. In this review, we focus on the compositional changes in the gut microbiome and its related metabolites in various CVDs. Moreover, the potential treatment and preventive strategies targeting the gut microbiome and its metabolites are discussed.
Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology

Boyao Zhang,Thierry Schmidlin

DOI: https://doi.org/10.1038/s44324-024-00028-z

2024-09-23

Abstract:Abstract Traditional risk factors and biomarkers of cardiovascular diseases (CVD) have been mainly discovered through clinical observations. Nevertheless, there is still a gap in knowledge in more sophisticated CVD risk factor stratification and more reliable treatment outcome prediction, highlighting the need for a more comprehensive understanding of disease mechanisms at the molecular level. This need has been addressed by integrating information derived from multiomics studies, which provides systematic insights into the different layers of the central dogma in molecular biology. With the advancement of technologies such as NMR and UPLC-MS, metabolomics have become a powerhouse in pharmaceutical and clinical research for high-throughput, robust, quantitative characterisation of metabolic profiles in various types of biospecimens. In this review, we highlight the versatile value of metabolomics spanning from targeted and untargeted identification of novel biomarkers and biochemical pathways, to tracing drug pharmacokinetics and drug-drug interactions for more personalised medication in CVD research (Fig. 1).
Endothelial dysfunction: molecular mechanisms and clinical implications

Xia Wang,Ben He

DOI: https://doi.org/10.1002/mco2.651

2024-07-22

Abstract:Cardiovascular disease (CVD) and its complications are a leading cause of death worldwide. Endothelial dysfunction plays a crucial role in the initiation and progression of CVD, serving as a pivotal factor in the pathogenesis of cardiovascular, metabolic, and other related diseases. The regulation of endothelial dysfunction is influenced by various risk factors and intricate signaling pathways, which vary depending on the specific disease context. Despite numerous research efforts aimed at elucidating the mechanisms underlying endothelial dysfunction, the precise molecular pathways involved remain incompletely understood. This review elucidates recent research findings on the pathophysiological mechanisms involved in endothelial dysfunction, including nitric oxide availability, oxidative stress, and inflammation-mediated pathways. We also discuss the impact of endothelial dysfunction on various pathological conditions, including atherosclerosis, heart failure, diabetes, hypertension, chronic kidney disease, and neurodegenerative diseases. Furthermore, we summarize the traditional and novel potential biomarkers of endothelial dysfunction as well as pharmacological and nonpharmacological therapeutic strategies for endothelial protection and treatment for CVD and related complications. Consequently, this review is to improve understanding of emerging biomarkers and therapeutic approaches aimed at reducing the risk of developing CVD and associated complications, as well as mitigating endothelial dysfunction.
Illuminating the Molecular Intricacies of Exosomes and ncRNAs in Cardiovascular Diseases: Prospective Therapeutic and Biomarker Potential

Farheen Badrealam Khan,Shahab Uddin,Khang Wen Goh,Long Chiau Ming,Chrismawan Ardianto,Abdul Rasheed Palakot,Irfa Anwar,Mohsina Khan,Mohammad Owais,Chih-Yang Huang,Jayasimha Rayalu Daddam,Meraj Alam Khan,Shoaib Shoaib,Md Khursheed,Sara Reshadat,Hamid Reza Khayat Kashani,Sameer Mirza,Mohammed Akli Ayoub,Abozer Y. Elderdery,Abbas A. Khaleel

DOI: https://doi.org/10.3390/cells11223664

IF: 6

2022-11-19

Cells

Abstract:Cardiovascular diseases (CVDs) are one of the leading causes of death worldwide. Accumulating evidences have highlighted the importance of exosomes and non-coding RNAs (ncRNAs) in cardiac physiology and pathology. It is in general consensus that exosomes and ncRNAs play a crucial role in the maintenance of normal cellular function; and interestingly it is envisaged that their potential as prospective therapeutic candidates and biomarkers are increasing rapidly. Considering all these aspects, this review provides a comprehensive overview of the recent understanding of exosomes and ncRNAs in CVDs. We provide a great deal of discussion regarding their role in the cardiovascular system, together with providing a glimpse of ideas regarding strategies exploited to harness their potential as a therapeutic intervention and prospective biomarker against CVDs. Thus, it could be envisaged that a thorough understanding of the intricacies related to exosomes and ncRNA would seemingly allow their full exploration and may lead clinical settings to become a reality in near future.

cell biology
Molecular Mechanisms of Vascular Health: Insights From Vascular Aging and Calcification

Rajeev Malhotra,Elena Aikawa,Grace Gackenbach,Parag Goyal,Adam Johnson,Yabing Chen,Nadia R. Sutton,Cynthia St. Hilaire,Roger S. Blumenthal,Sagar U. Nigwekar,Catherine M. Shanahan,Dwight A. Towler,Brooke N. Wolford

DOI: https://doi.org/10.1161/ATVBAHA.122.317332

2022-11-22

Abstract:Cardiovascular disease is the most common cause of death worldwide, especially beyond the age of 65 years, with the vast majority of morbidity and mortality due to myocardial infarction and stroke. Vascular pathology stems from a combination of genetic risk, environmental factors, and the biologic changes associated with aging. The pathogenesis underlying the development of vascular aging, and vascular calcification with aging, in particular, is still not fully understood. Accumulating data suggests that genetic risk, likely compounded by epigenetic modifications, environmental factors, including diabetes and chronic kidney disease, and the plasticity of vascular smooth muscle cells to acquire an osteogenic phenotype are major determinants of age-associated vascular calcification. Understanding the molecular mechanisms underlying genetic and modifiable risk factors in regulating age-associated vascular pathology may inspire strategies to promote healthy vascular aging. This article summarizes current knowledge of concepts and mechanisms of age-associated vascular disease, with an emphasis on vascular calcification.
Omics research in atherosclerosis

Kai-Jiang Tian,Yu Yang,Guo-Shuai Chen,Nian-Hua Deng,Zhen Tian,Rui Bai,Fan Zhang,Zhi-Sheng Jiang

DOI: https://doi.org/10.1007/s11010-024-05139-1

2024-10-24

Abstract:Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid deposition within the arterial intima, as well as fibrous tissue proliferation and calcification. AS has long been recognized as one of the primary pathological foundations of cardiovascular diseases in humans. Its pathogenesis is intricate and not yet fully elucidated. Studies have shown that AS is associated with oxidative stress, inflammatory response, lipid deposition, and changes in cell phenotype. Unfortunately, there is currently no effective prevention or targeted treatment for AS. The rapid advancement of omics technologies, including genomics, transcriptomics, proteomics, and metabolomics, has opened up novel avenues to elucidate the fundamental pathophysiology and associated mechanisms of AS. Here, we review articles published over the past decade and focus on the current status, challenges, limitations, and prospects of omics in AS research and clinical practice. Emphasizing potential targets based on omics technologies will improve our understanding of this pathological condition and assist in the development of potential therapeutic approaches for AS-related diseases.
Short-chain fatty acid, acylation and cardiovascular diseases.

Xiao-Feng Chen,Xiangqi Chen,Xiaoqiang Tang

DOI: https://doi.org/10.1042/CS20200128

2020-01-01

Clinical Science

Abstract:Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide. Metabolic dysfunction is a fundamental core mechanism underlying CVDs. Previous studies generally focused on the roles of long-chain fatty acids (LCFAs) in CVDs. However, a growing body of study has implied that short-chain fatty acids (SCFAs: namely propionate, malonate, butyrate, 2-hydroxyisobutyrate (2-HIBA), beta-hydroxybutyrate, crotonate, succinate, and glutarate) and their cognate acylations (propionylation, malonylation, butyrylation, 2-hydroxyisobutyrylation, beta-hydroxybutyrylation, crotonylation, succinylation, and glutarylation) participate in CVDs. Here, we attempt to provide an overview landscape of the metabolic pattern of SCFAs in CVDs. Especially, we would focus on the SCFAs and newly identified acylations and their roles in CVDs, including atherosclerosis, hypertension, and heart failure.
Vascular Proteomics: Linking Proteomic and Metabolomic Changes

Manuel Mayr,Ursula Mayr,Yuen‐Li Chung,Xiaoke Yin,John R. Griffiths,Qingbo Xu

DOI: https://doi.org/10.1002/pmic.200400947

2004-01-01

PROTEOMICS

Abstract:Cardiovascular diseases constitute the largest of death in the Western world. Various stressors, including elevated blood pressure, smoking, diabetes, and hypercholesterolemia directly or indirectly damage the vessel wall, eventually inducing arterial stiffness (arteriosclerosis) and lipid accumulation (atherosclerosis). However, the molecular mechanisms of atheroma formation are not yet fully clarified. While many investigators have used proteomic techniques to study cardiac diseases, vascular proteomics is still in its infancy. The present review highlights studies, in which proteomics has been successfully applied to study protein alterations in the vasculature. Furthermore, we will summarize our recent progress in combining proteomic and metabolomic techniques to reveal protein and metabolite alterations in the cardiovascular system: two‐dimensional (2‐D) gel electrophoresis proved to be highly complementary to nuclear magnetic resonance (NMR) spectroscopy, in that post‐translational modifications of the most abundant enzymes were displayed on 2‐D gels while NMR spectroscopy revealed changes in the corresponding metabolites. Importantly, the simultaneous assessment of protein and metabolite changes translated purely descriptive proteomic and metabolomic profiles into a functional context and provided important insights into pathophysiological mechanisms that would not have been obtained by other techniques.
Unraveling the complex interplay between Mitochondria-Associated Membranes (MAMs) and cardiovascular Inflammation: Molecular mechanisms and therapeutic implications

Xing Chen,Yang Yang,Zheng Zhou,Haihan Yu,Shuwei Zhang,Siyuan Huang,Ziqing Wei,Kaidi Ren,Yage Jin

DOI: https://doi.org/10.1016/j.intimp.2024.112930

2024-08-14

Abstract:Cardiovascular diseases (CVDs) represent a significant public health concern because of their associations with inflammation, oxidative stress, and abnormal remodeling of the heart and blood vessels. In this review, we discuss the intricate interplay between mitochondria-associated membranes (MAMs) and cardiovascular inflammation, highlighting their role in key cellular processes such as calcium homeostasis, lipid metabolism, oxidative stress management, and ERS. We explored how these functions impact the pathogenesis and progression of various CVDs, including myocardial ischemia-reperfusion injury, atherosclerosis, diabetic cardiomyopathy, cardiovascular aging, heart failure, and pulmonary hypertension. Additionally, we examined current therapeutic strategies targeting MAM-related pathways and proteins, emphasizing the potential of MAMs as therapeutic targets. Our review aims to provide new insights into the mechanisms of cardiovascular inflammation and propose novel therapeutic approaches to improve cardiovascular health outcomes.
Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction

Da Young Lee

DOI: https://doi.org/10.12997/jla.2024.13.3.262

Abstract:Cardiovascular disease (CVD) continues to be the primary cause of mortality worldwide, underscoring the importance of identifying additional cardiovascular risk factors. The consensus is that lipid levels alone do not fully reflect the status of atherosclerosis, thus necessitating extensive research on cardiovascular biomarkers. This review encompasses a wide spectrum of methodologies for identifying novel risk factors or biomarkers for CVD. Inflammation, oxidative stress, plaque instability, cardiac remodeling, and fibrosis play pivotal roles in CVD pathogenesis. We introduce and discuss several promising biomarkers-namely, osteocalcin, angiogenin, lipoprotein-associated phospholipase A2, growth differentiation factor 15, galectin-3, growth stimulation expressed gene 2, and microRNAs, all of which have potential implications in the assessment and management of cardiovascular risk.
Mechanistic insight of mitochondrial dysfunctions in cardiovascular diseases with potential biomarkers

Md. Nazmul Islam,Vineet Kumar Mishra,Rina Munalisa,Farzana Parveen,Saieeda Fabia Ali,Khadiza Akter,Tanvir Ahmed,Tsung-Jung Ho,Chih-Yang Huang

DOI: https://doi.org/10.1007/s13273-023-00424-4

2024-02-21

Molecular & Cellular Toxicology

Abstract:Acceleration of atherogenesis is an aftermath of cardiovascular diseases (CVDs), which arise with mitochondrial dysfunction (MD). Endothelium restraint inflammation, repair and fluidic exchange with nearby tissues. Endothelium-mediated mitochondrial damage can trigger the molecular mechanisms of vasodilation, pro-inflammation and process of pro-thrombotic accumulation in microvascular endothelial layer. The oxidation of lipid particles generates modified lipoproteins. Modification of mitochondrial function recently emerged a great concern towards the atherosclerosis initiation and progression, because the powerhouse of energy production mitochondria mutation can release mtDNA into cytoplasm and it can be act as sensor for viral DNA or foreign DNA. Another cause is mitochondrial imbalance can lead to product excess amount of reactive oxygen species (ROS) which can cause cellular metabolism and respiration system.

toxicology
Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases

Jing Xu,Yuejin Yang

DOI: https://doi.org/10.1080/19490976.2021.1936379

IF: 12.2

2021-01-01

Gut Microbes

Abstract:<span>Cardiovascular diseases (CVDs) still remain the leading concern of global health, accounting for approximately 17.9 million deaths in 2016. The pathogenetic mechanisms of CVDs are multifactorial and incompletely understood. Recent evidence has shown that alterations in the gut microbiome and its associated metabolites may influence the pathogenesis and progression of CVDs such as atherosclerosis, heart failure, hypertension, and arrhythmia, yet the underlying links are not fully elucidated. Owing to the progress in next-generation sequencing techniques and computational strategies, researchers now are available to explore the emerging links to the genomes, transcriptomes, proteomes, and metabolomes in parallel meta-omics approaches, presenting a panoramic vista of culture-independent microbial investigation. This review aims to outline the characteristics of meta-omics pipelines and provide a brief overview of current applications in CVDs studies which can be practical for addressing crucial knowledge gaps in this field, as well as to shed its light on cardiovascular risk biomarkers and therapeutic intervention in the near future.</span>

gastroenterology & hepatology,microbiology
Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning

Xu Zhou,Xinhao Sun,Hongwei Zhao,Feng Xie,Boyan Li,Jin Zhang

DOI: https://doi.org/10.1038/s41598-024-77352-3

IF: 4.6

2024-10-30

Scientific Reports

Abstract:Cardiovascular disease (CVD) is the leading cause of mortality, disability, and healthcare costs, with a significant impact on the elderly and contributing to premature deaths across various age groups, including those below age 70. Despite decades of transformative discoveries and clinical efforts, the challenges of diagnosis, prevention, and treatment of CVD persist on a massive scale. This study aimed to unravel potential CVD-associated biomarkers and establish a machine learning model for the risk assessment of CVD. Untargeted metabolic assay with ultra-high performance liquid chromatography-tandem mass spectrometry and routine clinical biochemistry test were undertaken on the fasting venous blood specimens from 57 subjects. Four relevant clinical traits and 164 CVD-associated metabolites were identified, especially those related to glycerophospholipid metabolism and biosynthesis of unsaturated fatty acids. The machine learning model achieved from an integrated biomarker panel of palmitic amide, oleic acid, 138-pos (the 138th detected metabolomic feature in positive ion mode), phosphatidylcholine, linoleic acid, age, direct bilirubin, and inorganic phosphate, was able to improve the accuracy of CVD risk assessment up to a high satisfactory value of 0.91. The findings indicate that disorders in the metabolic processes of biological membranes and energy are significantly associated with increased risk of vascular damage in CVD patients. With machine learning methods, the pivotal metabolites and clinical biomarkers offer a promising potential for the efficient risk assessment and diagnosis of CVD.

multidisciplinary sciences
Current Research for Heart Disease Biology and Therapeutics

Claudia Kusmic

DOI: https://doi.org/10.3390/ijms251910744

IF: 5.6

2024-10-06

International Journal of Molecular Sciences

Abstract:first_page Download PDF settings Order Article Reprints Font Type: Arial Georgia Verdana Font Size: Aa Aa Aa Line Spacing:    Column Width:    Background: Open Access Editorial Current Research for Heart Disease Biology and Therapeutics by Claudia Kusmic Claudia Kusmic SciProfiles Scilit Preprints.org Google Scholar Institute of Clinical Physiology, National Research Council (CNR), 56124 Pisa, Italy Int. J. Mol. Sci. 2024 , 25 (19), 10744; https://doi.org/10.3390/ijms251910744 (registering DOI) Submission received: 3 October 2024 / Accepted: 5 October 2024 / Published: 6 October 2024 (This article belongs to the Special Issue Current Research for Heart Disease Biology and Therapeutics) Download keyboard_arrow_down Download PDF Download XML Versions Notes Cardiac and vascular diseases are the leading cause of death globally. Heart disease covers a wide range of structural and functional changes that affect the heart, including conditions like coronary artery disease, abnormal heart rhythms, congenital heart defects, valve disease, and heart failure (HF). In many cases, less severe forms of heart disease have the potential to advance or intersect with other conditions, possibly leading to a more significant pathological outcome, including severe HF. Heart failure is a significant public health challenge due to its high prevalence and severe impact on patients and healthcare systems. It affects about 2% of the global population and is expected to increase due to ageing populations and improved survival rates from other cardiac conditions. By 2030, it is projected that nearly 50% of the population over 60 years of age will be affected by HF [1,2]. Cardiac research has increasingly focused on exploring new and innovative approaches to better understand the biological basis of cardiac disease onset and progression, as well as to develop novel therapeutic approaches that target molecular pathways involved in the transition to pathophysiological conditions.This Special Issue of the International Journal of Molecular Science features four research articles and six reviews that cover various aspects of cardiac pathophysiology. These contributions include studies of basic research and therapeutic and functional approaches. They also provide new insights into potential molecular targets for therapeutic strategies and new diagnostic and prognostic markers in heart disease.Two reviews specifically address different aspects of acute myocardial infarction (MI). In particular, Salvadori and colleagues thoroughly analyse and critically discuss the latest research on epigenetic changes following myocardial infarction (MI). They specifically examine the role of miRNAs and their interaction with important signalling pathways in the different early stages of the healing process after an ischemic event, namely the inflammation, resolution, and maturation phases [3]. Additionally, they shed light on the differences in the risk factors and long-term outcomes for MI between males and females.Zheng et al. revisit the role of vitamin C, a well-established antioxidant that reduces oxidative stress [4]. The beneficial role of vitamin C in the cardiovascular system remains controversial, and previous studies on the association between vitamin C levels and MI have shown conflicting results. Although vitamin C demonstrates a strong antioxidant function at both the cell -Abstract Truncated-

biochemistry & molecular biology,chemistry, multidisciplinary
The Application of Single-Cell Technologies in Cardiovascular Research

Yinan Chen,Yang Liu,Xiang Gao

DOI: https://doi.org/10.3389/fcell.2021.751371

IF: 5.5

2021-10-11

Frontiers in Cell and Developmental Biology

Abstract:Cardiovascular diseases (CVDs) are the leading cause of deaths in the world. The intricacies of the cellular composition and tissue microenvironment in heart and vasculature complicate the dissection of molecular mechanisms of CVDs. Over the past decade, the rapid development of single-cell omics technologies generated vast quantities of information at various biological levels, which have shed light on the cellular and molecular dynamics in cardiovascular development, homeostasis and diseases. Here, we summarize the latest single-cell omics techniques, and show how they have facilitated our understanding of cardiovascular biology. We also briefly discuss the clinical value and future outlook of single-cell applications in the field.

cell biology,developmental biology

Molecular Aspects of Cardiovascular Risk Factors

Cellular and molecular biology of posttranslational modifications in cardiovascular disease

Exosomes and Their Derivatives As Biomarkers and Therapeutic Delivery Agents for Cardiovascular Diseases: Situations and Challenges.

Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Research progress on post-translational modification of proteins and cardiovascular diseases

Cellular Senescence, Mitochondrial Dysfunction, and Their Link to Cardiovascular Disease

The Gut-Heart Axis: Updated Review for The Roles of Microbiome in Cardiovascular Health

Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology

Endothelial dysfunction: molecular mechanisms and clinical implications

Illuminating the Molecular Intricacies of Exosomes and ncRNAs in Cardiovascular Diseases: Prospective Therapeutic and Biomarker Potential

Molecular Mechanisms of Vascular Health: Insights From Vascular Aging and Calcification

Omics research in atherosclerosis

Short-chain fatty acid, acylation and cardiovascular diseases.

Vascular Proteomics: Linking Proteomic and Metabolomic Changes

Unraveling the complex interplay between Mitochondria-Associated Membranes (MAMs) and cardiovascular Inflammation: Molecular mechanisms and therapeutic implications

Emerging Circulating Biomarkers for Enhanced Cardiovascular Risk Prediction

Mechanistic insight of mitochondrial dysfunctions in cardiovascular diseases with potential biomarkers

Gut microbiome and its meta-omics perspectives: profound implications for cardiovascular diseases

Biomarker identification and risk assessment of cardiovascular disease based on untargeted metabolomics and machine learning

Current Research for Heart Disease Biology and Therapeutics

The Application of Single-Cell Technologies in Cardiovascular Research